PapersPMID:40795809
Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“The composite of BPD or death (RR: 0.95; 95% CI: 0.83-1.10; p = 0.53; I2 = 50.2%), BPD (RR: 0.98; 95% CI: 0.83-1.15; p = 0.77; I2 = 38.1%), death (RR: 0.88; 95% CI: 0.66-1.19; p = 0.41; I2 = 0%), NEC (RR: 0.94; 95% CI: 0.69-1.26; p = 0.67; I2 = 0%), IVH (RR: 1.22; 95% CI: 0.89-1.68; p = 0.22; I2 = 3.5%), RoP (RR: 1.35; 95% CI: 0.43-4.28; p = 0.61; I2 = 76.3%), duration of mechanical ventilation (MD: 0.13; 95% CI: -1.35 to 1.60; p = 0.87; I2 = 0%), and postnatal corticosteroid requirement (RR: 0.84; 95% CI: 0.64-1.08; p = 0.18; I2 = 34.5%) were similar between the groups.”
- Study
- meta-analysis
- Effect
- 0.13 mean difference, 95% CI −1.35 to 1.6
- Population
- preterm infants (meta-analysis of 6 RCTs, 1,360 infants; azithromycin vs placebo, whole population not restricted by Ureaplasma status)
Study record
- Design
- meta-analysis
- Species
- human
- Population
- preterm infants
- Participants
- 1,360
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 8